Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- KEYNOTE-361 Investigators
- St Bartholomew's Hospital
- Barts and The London School of Medicine and Dentistry
- Hetényi Géza Hospital
- Istanbul University
- National Cancer Center Hospital East
- National Institute of Oncology
- Sunnybrook Odette Cancer Centre
- Unité de Recherche en Santé Publique (CHUQ)
- Universite Paris Cite
- University of Antwerp
- Integrated Cancer Center Ghent
- Vall d'Hebron Institute of Oncology (VHIO)
- Leon Berard Center
- Memorial Antalya Hospital
- Mayo Clinic Scottsdale-Phoenix, Arizona
- Metabolomics and Cell Biology Platforms
- Hospital del Mar
- University of Pennsylvania
- University of Washington
- Fred Hutchinson Cancer Research Center
- Inc.
- University of Michigan Health System
Research output: Contribution to journal › Article › peer-review
592
Citations
(Scopus)